Cochlear Limited 2026 연례 수익은 AUD 2.3억으로 2% 상승을 기록했으며, 지속된 화가에 의한 수익은 AUD 322억을 기록했습니다.

Australian hearing implant maker의 주가는 AUD 2.3억에서 AUD 2.3억 7.19% 상승으로 $140.69에서 $131.25로 상승했습니다.

재정 예상

2027 연례에 regards Cochlear expects constant-currency revenue growth to remain in the low single digits, with underlying net profit forecast at AUD 330 million to AUD 350 million. Gross margin is expected at 70% to 71%, with operating expenses declining slightly.

CEO Dig Howitt said the company's mission remains central to its work, enabling over 55,000 people to hear for the first time or regain their hearing in FY 2026. He also pointed to the long-term growth opportunity in adult hearing loss, with the clinical need significant and adult penetration remaining low.

제품 pipeline

Howitt said Nexa is the base for future growth, with two important implant developments driving growth: drug-eluting electrodes and the totally implantable cochlear implant. CFO Sarah noted that cost control and cloud investments are creating lasting savings, with free cash flow improving sharply in FY 2026.